An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors

NCT03349073 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Refractory Solid Tumors

Interventions

DRUG: T-1101 (Tosylate)

Sponsor

Taivex Therapeutics Corporation